Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490252 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0690-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0690-6 | ||
| 245 | 0 | 0 | |a Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features |h [Elektronische Daten] |c [Yu Lim, Il Kim, Tae Han, Seung Choi, Sung-Hye Park, Chul-Kee Park, Sun Paek, Se-Hoon Lee, Tae Kim] |
| 520 | 3 | |a Background: Although the optimal treatment of frail glioblastoma patients is still controversial, previous randomized trials have excluded such patients. This study aimed to evaluate the feasibility and safety of hypofractionated radiotherapy (RT) with concomitant temozolomide for glioblastoma patients with poor prognostic features. Methods: We retrospectively reviewed 33 glioblastoma patients who underwent postoperative hypofractionated chemoradiotherapy. The patient criteria were either ≥70years or <70years with one or more risk factors: pre-RT performance status (ECOG score) ≥3, biopsy only, or rapid disease progression immediately after surgery. The median RT dose was 45Gy (range 30-45) with a fraction size of 3Gy. Results: The median age was 66.0years. Eighteen patients (55%) had poor pre-RT performance status (ECOG ≥3), and 16 patients (48%) underwent stereotactic biopsy only. The median overall survival (OS) and progression-free survival were 10.6 and 7.5months, respectively. Poor pre- and post-RT performance status [hazard ratio (HR) 3.12, 95% confidence interval (CI) 1.21-8.07 and HR 4.51, 95% CI 1.44-14.12, respectively] and no pseudoprogression (HR 5.43, 95% CI 1.58-18.61) were associated with poorer OS. While acute neurologic symptoms were reported in 5 patients (15%), toxicity profiles were acceptable without treatment-related aggravation of performance status. Conclusions: Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Glioblastoma |2 nationallicence | |
| 690 | 7 | |a Hypofractionated radiotherapy |2 nationallicence | |
| 690 | 7 | |a Temozolomide |2 nationallicence | |
| 690 | 7 | |a Poor performance status |2 nationallicence | |
| 690 | 7 | |a Elderly |2 nationallicence | |
| 700 | 1 | |a Lim |D Yu |u Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Kim |D Il |u Department of Radiation Oncology, Cancer Research Institution, Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Han |D Tae |u Department of Radiation Oncology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Choi |D Seung |u Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Park |D Sung-Hye |u Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Park |D Chul-Kee |u Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Paek |D Sun |u Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Lee |D Se-Hoon |u Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 700 | 1 | |a Kim |D Tae |u Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 21-28 |x 1341-9625 |q 20:1<21 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0690-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0690-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lim |D Yu |u Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kim |D Il |u Department of Radiation Oncology, Cancer Research Institution, Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Han |D Tae |u Department of Radiation Oncology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Choi |D Seung |u Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Park |D Sung-Hye |u Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Park |D Chul-Kee |u Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Paek |D Sun |u Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lee |D Se-Hoon |u Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kim |D Tae |u Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 21-28 |x 1341-9625 |q 20:1<21 |1 2015 |2 20 |o 10147 | ||